Exelixis | EXEL - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Acadia Pharmaceuticals USD 976.45M 19.97M 2026-09
Agios Pharmaceuticals USD 128.55M 28.9M 2026-09
Akebia Therapeutics USD 159.25M 3.71M 2026-09
Amgen USD 13.19B 799M 2026-09
AstraZeneca USD 4.89B 2.67B 2026-06
Bayer EUR 4.29B 1.44B 2026-06
BioMarin Pharmaceutical USD 736.01M 138M 2026-09
Bristol-Myers Squibb USD 9.57B 852M 2026-09
Cytokinetics USD 203.43M 51.84M 2026-09
Eisai JPY 245.42B 56.22B 2026-03
Eli Lilly USD 4.89B 4.07B 2026-09
Exelixis USD 304.77M 23.33M 2026-09
Genmab DKK 1.5B 18M 2026-06
Glaxosmithkline GBP 2.93B 508M 2026-09
Incyte USD 3.85B 127.8M 2026-09
Ionis Pharmaceuticals USD 296.3M 53.76M 2026-09
MacroGenics USD 49.03M 64.88M 2026-09
Merck USD 9.55B 2.7B 2026-09
Moderna USD 1.2B 528M 2026-09
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Neurocrine Biosciences USD 641.5M 309.1M 2026-09
Novartis USD 8.87B 1.25B 2026-09
Pfizer USD 1.82B 848M 2026-09
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sanofi EUR 6.35B 806M 2026-06
Takeda JPY 418.53B 42.45B 2026-09
Ultragenyx Pharmaceutical USD 150M 25M 2026-09
Xencor USD 59.62M 14.96M 2026-09